⌘K
t
ImmuPharma PLC announced the appointment of Crowe LLP as its new auditor on 23 December 2024, succeeding CLA Evelyn Partners Limited with immediate effect. Crowe will conduct the audit of the Company's financial statements for the financial year ending 31 December 2024. A proposal for their re-appointment will be subject to shareholder approval at the 2025 Annual General Meeting.
| Date | 23 Dec 2024 |
| Time | 07:00:06 |
| Category | Corporate updates |
| ID | 0145R |
23 December 2024
ImmuPharma PLC
("ImmuPharma" or the "Company")
Change of Auditor
ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company, announces the appointment of Crowe LLP ("Crowe") as the Company's new auditor, succeeding CLA Evelyn Partners Limited, with immediate effect.
Crowe will conduct the audit of the Company's financial statements for the financial year ending 31 December 2024 and a proposal to reappoint them as auditors of the Company will be subject to the approval of shareholders at the 2025 Annual General Meeting.
|
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140,is a first-in class "immune tolerance restorer" for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models suggest therapeutic activity for many other autoimmune diseases that share the same mechanism of action.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.